secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001655759-23-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas Q1 net loss widens to $81.9M; vepdegestrant combo shows 60.7% CBR
-------------------------------------------------------------------------

- Net loss of $81.9M for Q1 2023 vs $63.4M in Q1 2022; revenue increased to $32.5M from $26.5M.
- Cash, equivalents, and marketable securities of $1.129B, with expected runway into 2026.
- R&D expenses rose to $95.3M (up 49% YoY) driven by increased pipeline investment and Pfizer cost sharing.
- Vepdegestrant + palbociclib Phase 1b (Part C) showed 60.7% CBR in heavily pretreated ER+/HER2- mBC patients.
- Plans to initiate Phase 3 safety lead-in for vepdegestrant + palbociclib in 1L mBC in 2H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575923000039/0001655759-23-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575923000039/arvn-20230505.htm
  HTML page:      https://secwatch.observer/filing/0001655759-23-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer